Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Takeaways - MDSpire

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • By

  • Eva Domingo-Domènech

  • Barbara Pro

  • Tim Illidge

  • Steven Horwitz

  • Lorenz Trumper

  • Swami Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Won-Seog Kim

  • Tatyana Feldman

  • Ilseung Choi

  • Giuseppe Gritti

  • David Belada

  • Andrei Shustov

  • Arpad Illes

  • Pier Luigi Zinzani

  • Andreas Hüttmann

  • Marek Trneny

  • Steven Le Gouill

  • Deepa Jagadeesh

  • Jonathan W. Friedberg

  • Meredith Little

  • Cassie Dong

  • Michelle Fanale

  • Keenan Fenton

  • Kerry J. Savage

  • January 28, 2026

  • 0 min

Share

  • 1

    The article corrects a misinterpretation regarding 5-year progression-free survival (PFS) rates in ALK– sALCL patients.

  • 2

    The corrected statement specifies that the PFS rates apply to ALK– sALCL patients who achieved a complete response.

  • 3

    In the A + CHP and CHOP arms, the estimated 5-year PFS rates for patients with complete response were 56.8% and 56.0%, respectively.

  • 4

    The original article was published on August 1, 2025, and the correction aims to clarify previously ambiguous data.

  • 5

    Data on 5-year PFS in ALK– disease, irrespective of response, is illustrated in Figure 1 of the original article.

Original Source(s)

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

  • January 28, 2026

Related Content

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min
Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches